VNDA Vanda Pharmaceuticals Inc

Price (delayed)

$5.03

Market cap

$304.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.63

Enterprise value

$266.45M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 27
Relative Valuation: Rel. Valuation: 26
Relative Profitability: Rel. Profitability: 18

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more ...

Highlights
The revenue has increased by 6% YoY
The gross profit has increased by 5% YoY
VNDA's debt has surged by 162% year-on-year and by 158% since the previous quarter
Vanda Pharmaceuticals's equity has shrunk by 55% YoY and by 22% QoQ

Key stats

What are the main financial stats of VNDA

VNDA stock price

How has the Vanda Pharmaceuticals stock price performed over time
Intraday
-3.08%
1 week
-1.66%
1 month
-16.17%
1 year
15.37%
YTD
-42.97%
QTD
-17.81%

Financial performance

How have Vanda Pharmaceuticals's revenue and profit performed over time
Revenue
$215.72M
Gross profit
$202.22M
Operating income
-$185.67M
Net income
-$274.85M
Gross margin
93.7%
Net margin
-127.4%
The operating income has plunged by 84% YoY and by 16% from the previous quarter
VNDA's operating margin has shrunk by 74% YoY and by 17% QoQ
VNDA's net margin is down by 16% since the previous quarter
VNDA's net income is down by 15% since the previous quarter

Price vs fundamentals

How does VNDA's price correlate with its fundamentals

Growth

What is Vanda Pharmaceuticals's growth rate over time

Valuation

What is Vanda Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.37
P/S
1.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.24
The company's EPS fell by 14% QoQ
Vanda Pharmaceuticals's equity has shrunk by 55% YoY and by 22% QoQ
VNDA's P/B is 52% above its 5-year quarterly average of 0.9 and 5% above its last 4 quarters average of 1.3
VNDA's P/S is 26% below its last 4 quarters average of 1.9 and 22% below its 5-year quarterly average of 1.8
The revenue has increased by 6% YoY

Efficiency

How efficient is Vanda Pharmaceuticals business performance
The company's return on sales has shrunk by 96% YoY and by 20% QoQ
Vanda Pharmaceuticals's ROIC has plunged by 56% from the previous quarter
Vanda Pharmaceuticals's return on equity has decreased by 38% QoQ
Vanda Pharmaceuticals's ROA has decreased by 27% from the previous quarter

Dividends

What is VNDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VNDA.

Financial health

How did Vanda Pharmaceuticals financials performed over time
The total assets is 115% higher than the total liabilities
VNDA's quick ratio has plunged by 54% YoY and by 27% from the previous quarter
The current ratio has dropped by 50% year-on-year and by 25% since the previous quarter
VNDA's debt is 92% smaller than its equity
Vanda Pharmaceuticals's debt to equity has soared by 167% from the previous quarter
VNDA's debt has surged by 162% year-on-year and by 158% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.